LCN2 and prostate cancer: In particular, MMP-9/NGAL enzymatic activity was observed in the urine of breast cancer patients but not in healthy controls (21), and in 50% of urine samples from prostate cancer patients and in 49% of the urine from bladder cancer patients (22).